Aldeyra Therapeu (ALDX) Stock Price, Quote & News

Company Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally admini...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 761 4904

Fax: 339 674 6495

Website: www.aldeyra.com

Address:

131 Hartwell Avenue, Suite 320, Lexington, United States

MewKitty Aug. 28 at 4:29 AM

$ALDX FYI - LEGAL UPDATE per ChatGPT-5: Judge Levenson issued a Memorandum & Order Aug 10, 2026 Massachusetts Federal District Court, docket # 1:26‑cv‑11510 - S. Albonico appointed lead plaintiff, highest estimated loss >300K - Orrell and Bustamante motions are DENIED for lead plaintiff, lower losses - Rosen Law Firm approved as lead counsel per lead plaintiff request - ALDX has retained Goodwin Procter LLP for legal defense. Both Rosen & GP are heavy hitters in securities fraud. - Scheduling Order (Aug 11–12, 2026) set the litigation calendar: TIMELINE: Amended/Expanded Complaint - Oct 9, 2026 - Access it through PACER Defendants’ Answer or Motion to Dismiss - Dec 8, 2026 Plaintiff Opposition to Motion to Dismiss - Jan 22, 2027 Defendants' Reply - Feb 22, 2027 Stay tuned - GLTA

0 · Reply

prismmarketview Aug. 26 at 2:41 PM

Bausch + Lomb is taking its dual-action dry eye drop to Phase 3 after a Phase 2 study told it when to measure. The combination showed a significant improvement over Xiidra alone at Day 15, ahead of the Day 29 timepoint the company had originally chosen. The FDA accepts Day 15 for registrational studies, so the pivotal program will be built around it. In dry eye, knowing when to measure can matter as much as what you are measuring. Aldeyra, Palatin and OKYO are each working through their own version of that question. $BLCO $ALDX $PTN $OKYO https://prismmarketview.com/bausch-lomb-missed-its-dry-eye-endpoint-the-result-still-points-to-phase-3/

0 · Reply

RigidFlexibility Aug. 25 at 7:25 PM

$ALDX …quiet in here. At a LOSS…..for words? Heavy bags here. Sold only a little to buy other prospects. C’mon CEO, say something. Or not. Lol. Lord, bring us back from the dead please. GLTA.

3 · Reply

Biotech_Pharma_Investor Aug. 19 at 7:24 PM

$ALDX I think a resolution on this regulatory saga may be closer than the market thinks. Asymmetric risk-reward (but still significant downside risk given a current market valuation 2x cash). My summary for anyone interested: https://substack.com/@biotechpharmainvestor/note/c-318286245?r=2nece1&utm_source=notes-share-action&utm_medium=web

0 · Reply

philipv777 Aug. 19 at 4:54 PM

$ALDX as far as I understand, aldeyra should currently be getting their ducks in a row for an FDR/appeal. The likelihood of an agreement with the FDA without the FDR is very unlikely. Im sure lawyers are heavily involved which would explain why Todd didn't jump straight to FDR aftr last type a and went w/ this 'type D' to tie up loose ends. This desperately needs some direction; the limbo (especially after FOUR total CRL's) has left this with ZERO credibility and im not sure Type D will really resolve all my concerns at this point but it's a start.

0 · Reply

PeterV9764 Aug. 18 at 5:23 PM

$ALDX Philip I wouldn’t be surprised if we get some sort of news by next week! I take that as a good sign

1 · Reply

philipv777 Aug. 18 at 3:43 PM

$ALDX something’s cookin!

1 · Reply

DavidScott Aug. 17 at 3:19 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $NMAX $BYND $INO $ALDX $CAN

0 · Reply

DavidScott Aug. 14 at 8:00 PM

$ONFO $NMAX $INO $BYND $ALDX = Great job bulls! It was a solid session today for these movers (especially with some of these choppy conditions). These were our team's best trades this round! We are bullish and expecting even more action on these names again going into Monday. If you need any guidance or a mentor, then feel free to join our team anytime! ✅🤝 Have a great weekend everyone! 🎉

1 · Reply

VoxGeorge Aug. 13 at 11:06 PM

$ALDX

1 · Reply

Aldeyra Therapeutics Quarterly report: Q2 2026

Jul 7, 2026, 4:00 AM EDT - 7 weeks ago

Levicept Appoints Darlene Deptula-Hicks as CFO

Jun 9, 2026, 8:30 PM EDT - 2 months ago

Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors

Jun 4, 2026, 8:45 AM EDT - 3 months ago

Aldeyra Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 7:01 AM EDT - 3 months ago

Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

2026-05-27T09:59:56.000Z - 3 months ago

Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims

May 7, 2026, 7:00 AM EDT - 4 months ago

Aldeyra Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 6:39 PM EDT - 4 months ago

REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Aldeyra Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Aldeyra Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 8:00 PM EDT - 4 months ago

ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role

Apr 20, 2026, 4:32 PM EDT - 4 months ago

ADLX Stockholders Have Rights – If You Lost Money Investing in Aldeyra Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

2026-03-18T10:12:28.000Z - 5 months ago

Aldeyra downgraded to Neutral from Buy at H.C. Wainwright

Mar 17, 2026, 4:33 PM EDT - 5 months ago

Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-03-17T13:11:09.000Z - 5 months ago

FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy

2026-03-17T13:10:25.000Z - 5 months ago

How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?

Mar 17, 2026, 8:36 AM EDT - 5 months ago

US FDA declines to approve Aldeyra's drug for eye disorder

Mar 17, 2026, 8:30 AM EDT - 5 months ago

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

Feb 27, 2026, 7:00 AM EST - 6 months ago

Aldeyra Therapeutics Annual report: Q4 2025

Feb 25, 2026, 10:40 AM EST - 6 months ago

Aldeyra Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 7:01 AM EST - 6 months ago

Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Dec 16, 2025, 6:00 PM EST - 9 months ago

Aldeyra Therapeutics Slides: Corporate Presentation

Dec 16, 2025, 8:00 AM EST - 9 months ago

Aldeyra Therapeutics Transcript: Study Update

Dec 16, 2025, 8:00 AM EST - 9 months ago

Aldeyra Therapeutics Press release: Study Update

2025-12-16T01:05:11.000Z - 9 months ago

Aldeyra announces PDUFA extension for Reproxalap

Dec 15, 2025, 7:30 PM EST - 9 months ago

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Dec 4, 2025, 8:30 AM EST - 9 months ago

Aldeyra Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 6:30 AM EST - 10 months ago

Aldeyra Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Aldeyra Therapeutics Transcript: R&D Day 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Aldeyra Therapeutics Press release: FY 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Aldeyra Therapeutics Slides: FY 2025

2025-11-13T12:46:13.000Z - 10 months ago

Aldeyra expands RASP platform

Nov 13, 2025, 7:00 AM EST - 10 months ago

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Nov 11, 2025, 7:01 AM EST - 10 months ago

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:00 AM EST - 10 months ago

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

Nov 6, 2025, 7:00 AM EST - 10 months ago

Aldeyra Therapeutics Slides: Corporate Presentation

Nov 5, 2025, 4:00 PM EST - 10 months ago

Aldeyra Therapeutics Quarterly report: Q3 2025

2025-10-28T12:06:09.000Z - 10 months ago

Aldeyra ADX-629 achieves statistically significant improvement in liver function

Oct 28, 2025, 7:01 AM EDT - 10 months ago

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

2025-10-08T16:50:12.000Z - 11 months ago

Aldeyra price target raised to $7 from $6 at Jefferies

ABBV

Sep 8, 2025, 11:30 AM EDT - 1 year ago

Aldeyra Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:01 AM EDT - 1 year ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-28T11:16:06.000Z - 1 year ago

Aldeyra receives orphan designation from EMA for ADX-2191

Aug 28, 2025, 7:01 AM EDT - 1 year ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

2025-08-19T11:16:08.000Z - 1 year ago

Aldeyra granted fast track designation for ADX-2191 by FDA

Aug 19, 2025, 7:01 AM EDT - 1 year ago

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aug 13, 2025, 10:30 AM EDT - 1 year ago

Aldeyra Therapeutics Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 8, 2025, 4:00 PM EDT - 1 year ago

Aldeyra Therapeutics Slides: Corporate Presentation

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 7:01 AM EDT - 1 year ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

2025-07-24T11:26:18.000Z - 1 year ago

Aldeyra receives orphan designation for ADX-2191 from EMA

Jul 24, 2025, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

2025-07-17T11:05:30.000Z - 1 year ago

Aldeyra announces FDA acceptance for review of reproxalap NDA

Jul 17, 2025, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

2025-06-26T11:11:17.000Z - 1 year ago

Aldeyra receives special protocol assessment agreement letter from FDA

Jun 26, 2025, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Slides: Corporate Presentation

2025-06-17T11:10:56.000Z - 1 year ago

Aldeyra resubmits topical ocular reproxalap NDA to FDA

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Jun 5, 2025, 4:20 PM EDT - 1 year ago

Aldeyra Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 7:01 AM EDT - 1 year ago

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

May 14, 2025, 4:00 PM EDT - 1 year ago

Aldeyra Therapeutics Quarterly report: Q1 2025

May 7, 2025, 4:07 PM EDT - 1 year ago

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law

May 7, 2025, 8:46 AM EDT - 1 year ago

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)

May 6, 2025, 3:48 PM EDT - 1 year ago

ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss

May 6, 2025, 8:00 AM EDT - 1 year ago

Aldeyra Therapeutics Transcript: Study Update

May 6, 2025, 8:00 AM EDT - 1 year ago

Aldeyra Therapeutics Slides: Study Update

2025-05-05T22:40:06.000Z - 1 year ago

Aldeyra’s reproxalap achieves primary endpoint in Phase 3 dry eye disease trial

May 5, 2025, 6:34 PM EDT - 1 year ago

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

May 5, 2025, 4:00 PM EDT - 1 year ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

May 5, 2025, 3:38 PM EDT - 1 year ago

ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation

May 3, 2025, 7:18 AM EDT - 1 year ago

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

May 1, 2025, 8:08 AM EDT - 1 year ago

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company

Apr 30, 2025, 3:38 PM EDT - 1 year ago

ALDX ANNOUNCEMENT: Aldeyra Therapeutics, Inc. Investors may have been affected by Securities Violations - Contact BFA Law

Apr 29, 2025, 4:07 PM EDT - 1 year ago

ALDX NEWS: Aldeyra Therapeutics, Inc. is Being Investigated for Securities Violations - Investors are Alerted to Contact BFA Law

MewKitty Aug. 28 at 4:29 AM

0 · Reply

prismmarketview Aug. 26 at 2:41 PM

0 · Reply

RigidFlexibility Aug. 25 at 7:25 PM

$ALDX …quiet in here. At a LOSS…..for words? Heavy bags here. Sold only a little to buy other prospects. C’mon CEO, say something. Or not. Lol. Lord, bring us back from the dead please. GLTA.

3 · Reply

Biotech_Pharma_Investor Aug. 19 at 7:24 PM

0 · Reply

philipv777 Aug. 19 at 4:54 PM

0 · Reply

PeterV9764 Aug. 18 at 5:23 PM

$ALDX Philip I wouldn’t be surprised if we get some sort of news by next week! I take that as a good sign

1 · Reply

philipv777 Aug. 18 at 3:43 PM

$ALDX something’s cookin!

1 · Reply

DavidScott Aug. 17 at 3:19 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $NMAX $BYND $INO $ALDX $CAN

0 · Reply

DavidScott Aug. 14 at 8:00 PM

1 · Reply

VoxGeorge Aug. 13 at 11:06 PM

$ALDX

1 · Reply

SumDay1Day Aug. 7 at 3:37 PM

Im counting on the year to year August trend to exceed my expectations. Its been a patterns the past 8 years. $ALDX

0 · Reply

DavidScott Aug. 6 at 3:01 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $FUBO $NMAD $ALDX $NMAX $AAL

0 · Reply

SCSyndrome Aug. 5 at 4:39 AM

$ALDX TIME TO WAKE UP ALDX!!!! What’s the problem?

0 · Reply

Milanfinest Jul. 31 at 12:47 AM

$ALDX i hope the old days crew and also the idiot montana listened ti me when i left tents for nebius amd mu and co months ago

0 · Reply

DavidScott Jul. 30 at 2:43 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $AMC $ALDX $LCID $ACB $GME

1 · Reply

BUNEEe Jul. 29 at 10:50 PM

$ALDX dont get bored here, I will share with you my opportunity $GSUN another big popper of Chinese ticker. Thank me later

0 · Reply

Merlintrader Jul. 29 at 6:46 PM

$ALDX Aldeyra Therapeutics Stock Hub: Reproxalap Type D Meeting Watch, the Full FDA Saga, AbbVie Optionality and the Post-CRL Pipeline Reset https://www.merlintrader.com/aldeyra-therapeutics-stock-hub/

1 · Reply

PeterV9764 Jul. 24 at 10:26 AM

$ALDX FYI

1 · Reply

GoldmanSlaps Jul. 22 at 7:48 PM

$ALDX seeint unusally large bid and asks reminds me $ADMA before take off

3 · Reply

mimiwor Jul. 16 at 2:18 PM

$ALDX Red to green close is happening here come on in...

1 · Reply

TripleGateCptl Jul. 15 at 11:13 PM

$ALDX We have seen this movie before. FDA wanted some "housekeeping" information last year, when they delayed the PDUFA and asked ALDX to file the failed trail data. I'm sure Todd gonna say this is just more "housekeeping" stuff they need to resolve, before the FDA realizes what an awesome product this is. Because it works for 20 minutes, just not in real life.

2 · Reply

rahmanoof Jul. 15 at 10:43 PM

$ALDX this will always recover, type d meeting or type Z , nothing matters

0 · Reply

Market Cap	92.90M
Revenue (ttm)	0.00
Net Income (ttm)	-33.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	547,900
Avg Vol	1,367,184
Day's Range	N/A - N/A
Shares Out	60.33M
Stochastic %K	18%
Beta	1.21
Analysts	Strong Sell
Price Target	$6.25